Arrowhead Pharmaceuticals Inc. recently held a conference call to discuss their fiscal 2025 second quarter results, which ended on March 31, 2025. The call featured key members of the management team, including President and CEO Dr. Chris Anzalone and interim Chief Medical Scientist Dr. Bruce Given. During the call, Dr. Chris Anzalone highlighted the company's strong financial position, stating, "Arrowhead is at an important point both in terms of capabilities and potential value as we drive our organization toward our first commercial launch, which we anticipate this year." The discussion also covered the planned launch of plozasiran, pending regulatory review and approval, marking the company's transition from a development stage to a commercial stage. Dr. Anzalone emphasized the combination of commercial expansion, a productive discovery engine, and a strong balance sheet as key factors contributing to the company's stability and potential upside. The call also marked the retirement of Ken, a valuable team member, with Dr. Anzalone expressing gratitude for his contributions over the past 16 years, and welcomed Dan Apel as the new CFO at this critical juncture for Arrowhead. The full transcript can be accessed through the link below.